Cidara Therapeutics, Inc. (NASDAQ: CDTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
Cidara Therapeutics GAAP EPS of -$2.38 beats by $1.87 [Seeking Alpha]
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results